PO.ET07.01 · 实验与分子治疗
Quantitative Pharmacology and Translational Modeling
-
-
- 1815 1815 SBE303的非临床表征：一种靶向nectin-4、搭载新型拓扑异构酶1抑制剂的抗体药物偶联物（ADC）显示出良好的安全边界 Nonclinical characterization of SBE303: A nectin-4 targeted antibody drug conjugate (ADC) with novel topoisomerase 1 inhibitor shows a favorable safety margin Ji Yeon Kim, Sungwoo Hyung, Hyun-Ji Choi, Songhyun Lim, Jae Hee Lee, Seokuee Kim, Donghyun Kim, So-Shin Ahn, Donghoon Shin
-
-
- 1819 1819 OBI-904，一种基于聚糖的位点特异性Nectin-4靶向ADC，在非临床研究中表现出强效持久的抗肿瘤活性、改善的PK特征并克服EV耐药 OBI-904, a glycan-based site-specific Nectin-4-targeted ADC, demonstrates potent and durable antitumor activity with an improved PK profile and overcoming EV-resistance in non-clinical studies Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen
- 1820 1820 raludotatug deruxtecan（R-DXd）的药代动力学-肿瘤生长抑制建模，以支持铂耐药卵巢癌（PROC）的3期剂量选择 Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC) YoungJun Yoo, Kevin Koloskoff, Sandra Re, Izna Ali, Felipe K. Hurtado, Raouf El Cheikh
- 1821 1821 CS5006的临床前疗效与安全性，一种搭载拓扑异构酶1抑制剂载荷的新型整合素beta4靶向抗体药物偶联物 Preclinical efficacy and safety of CS5006, a novel integrin beta4-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload Chuan Wang, Xinling Zhang, Ning Zhang, Yamin Wang, Yongwang Li, Mengyao Zhu, Xuelian Liu, Yaxin Chen, Yuxin Qian, Yongli Yang, Jingyu Sun, Fei Ma, Jianxin Yang
- 1822 1822 CS5008的临床前疗效与安全性，一种搭载拓扑异构酶1抑制剂载荷、用于小细胞肺癌和神经内分泌肿瘤的新型SSTR2×DLL3双特异性抗体药物偶联物（ADC） Preclinical efficacy and safety of CS5008, a novel SSTR2×DLL3 bispecific antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor payload for small cell lung cancer and neuroendocrine tumors Chuan Wang, Yongwang Li, Ning Zhang, Yamin Wang, Xinling Zhang, Xuelian Liu, Yuxin Qian, Hui Dai, Xueqin Dai, Yaxin Chen, Zicong Zheng, Wenjing Xiang, Fei Ma, Jianxin Yang
- 1823 1823 CS5007的临床前疗效与安全性，一种搭载拓扑异构酶1抑制剂载荷的EGFR×HER3双靶向抗体药物偶联物 Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload Chuan Wang, Yamin Wang, Ning Zhang, Xinling Zhang, Yongwang Li, Yuxin Qian, Yaxin Chen, Yongli Yang, Xuelian Liu, Mengyao Zhu, Hui Dai, Wenjing Xiang, Xueqin Dai, Fei Ma, Jianxin Yang
-
-
- 1826 1826 暴露-反应分析和定量系统药理学建模用于DLBCL患者中surovatamig的最佳剂量选择 Exposure-response analysis and quantitative systems pharmacology modeling for an optimal dose selection of surovatamig in patients with DLBCL Xu (Sue) Zhu, Damilola Olabode, Massimo Lai, Cesar Pichardo-Almarza, Meenu Pillai, Denise Brennan, David Sermer, Robin Lesley
-
- 1828 1828 选择性强效EP300降解剂的临床前评估在血液系统恶性肿瘤中展示出强大的抗肿瘤活性和良好的耐受性 Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies Meiyun Lin, Wesley Austin, Qianhe Zhuo, Rieko Arimoto, Karolina Mizeracka, Abira Ramakrishnan, Kevin Wilson, Elizabeth Wittenborn, Laura La Bonte, Steven Bellon
-
- 1830 1830 SP09253，一种口服生物利用度高、高效力的RAS(ON)分子胶抑制剂，在KRAS突变肿瘤中展示出强大的抗肿瘤活性 SP09253, an orally bioavailable, highly potent RAS(ON) molecular glue inhibitor demonstrates robust anti-tumor activity in KRAS-mutant tumors Zherong Zhang, Xiaoyu Di, Qiming Sun
-
- 1832 1832 钙调蛋白-PCAIs结合亲和力的计算机模拟与体外抗癌细胞活力：抗泛突变KRAS药物开发策略 In silico calmodulin-PCAIs binding affinities versus in vitro anticancer cell viability: Strategies for the development of anti-pan-mutant KRAS agents Jahnissi Frimpomah Odoom, Kweku Ofosu-Asante, Joshua Kofi Ablordeppey, Desmond Kwakye, Amarender Burra, Nazarius Lamango
- 1833 1833 多聚异戊二烯化半胱氨酰胺抑制剂抑制生长，诱导多种KRAS突变肺癌细胞的细胞骨架和转录组重塑 Polyisoprenylated cysteinyl amide inhibitors suppress growth, induce cytoskeletal and transcriptomic remodeling in multiple KRAS -mutated lung cancer cells Desmond Kwakye, Chase Lilly, Kweku Ofosu-Asante, Jahnissi Frimpomah Odoom, Joshua Kofi Ablordeppey, Bianca Dal Bó, KARLA GONZALEZ, Chunli Yan, Matthew A. Gladstone, Kyle R. Phillips, Benjamin J. Ryder, Yong Huang, Ite A. Offringa, Nazarius Lamango
-
- 1835 1835 输液袋和生物基质中白消安稳定性的评价：在儿童常规治疗药物监测及适应性给药中的应用 Evaluation of busulfan stability in infusion bags and biological matrix: Application to routine therapeutic drug monitoring with adaptive dosing in children Marielle Jehanno, Jasmine Bettayeb, Guillaume Sicard, Arthur Sterin, Joseph Ciccolini
-
- 1837 1837 靶向Hippo/YAP-TEAD可增强darovasertib在葡萄膜黑色素瘤中的抗肿瘤活性 Targeting Hippo/YAP-TEAD increases the antitumor activity of darovasertib in uveal melanoma Rodolfo Daniel Cervantes-Villagrana, Elena Sofia Cardenas Alcoser, Kuniaki Sato, Simone Lubrano, Tomohiko Ishikawa, Andrew E. Aplin, J. Silvio Gutkind
-
